Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Merck & Co.
 More »

  • Leonard Schleifer Heads GEN's List of Top Money-Making Biopharma...
    CEO of Bristol-Myers Squibb (NYSE:BMY), $17,201,980; and Ken Frazier, chairman, president, and CEO of Merck & Co. (NYSE:MRK), $15,459,607. This year's list saw two key changes. ...
    8-5-2013
  • What the Top 15 Biopharma CEOs Are Making
    ... Chairman of the Board and CEO 2012 Compensation: $15,257,272 2011 Compensation: $15,615,645 % Change: -2.3% Position on 2012 List: #7 #5. Kenneth C. Frazier Company: Merck & Co. ...
    7-31-2013
  • Top 15 Pharma Companies of 2013
    climbed up the list (Novartis and Sanofi); four slipped a notch or more (Roche, Merck & Co., GlaxoSmithKline, and AstraZeneca); three companies were ranked the same as last ...
    7-19-2013
  • Xencor Licenses MAb Patent to Merck & Co.
    Xencor said today it awarded a nonexclusive license for one of its Fc engineering patents for a therapeutic monoclonal antibody to Merck & Co. The price was not disclosed, though ...
    7-2-2013
  • Top 15 Vaccines of 2012
    The list reveals, first off, how relatively few drug/vaccine developers are responsible for the top sellers. Merck & Co. and Sanofi account for more than half of the vaccines on ...
    7-2-2013
  • Assay Development Driving Personalized Medicine
    U.S. Centers for Medicare & Medicaid Services (CMS) has ... biomarkers team lead at Merck. "The most notable success ... and not prognostic, and co-developing a companion ...
    7-1-2013
  • In $1B Deal, Merck Sells API Business, 11-Drug Portfolio
    Aspen Group said today it will buy from Merck & Co. an active pharmaceutical ingredient manufacturing business with operations in the Netherlands and the U.S., as well as a ...
    6-27-2013
  • 10 Industry-Venture Fund Alliances
    Also notable is the presence of two pharma giants in several alliances: GlaxoSmithKline, listed in four of the listed alliances, and Merck & Co., a partner in three funds, two of ...
    6-20-2013
  • NanoSight Sets Sights on Exosomes
    ... Since its inception, NanoSight has installed more than 600 systems worldwide, for customers that include pharma giants GlaxoSmithKline, Merck & Co., Novartis, Pfizer, and Roche, as ...
    6-15-2013
  • Lilly Halts Phase II Study of Alzheimer's Candidate
    Lilly is one of five pharma giants with BACE inhibitors under development for the disease. The others are Merck & Co., which has launched a Phase II/III trial of its MK-8931; ...
    6-14-2013
  • Top 20 Corporate Venture Funds
    ... Currently seeking investments in North America, Europe, and the U.K. Year established: 2004 #4. Merck Research Ventures Fund (Merck & Co.) 6 Resources: $250 million evergreen fund. ...
    6-14-2013
  • Seeking New Tools Against Alzheimer's
    after releasing positive findings from a Phase IIb clinical trial last year. Merck & Co. late last year launched an 18-month Phase II/III trial comparing its MK-8931, a BACE ...
    6-7-2013
  • Pushing the Boundaries in Chromatography
    ... Origins of an Instrument Years ago, while managing a unit at Merck & Co.'s New Technologies Review and Licensing Committee, it occurred to Christopher Welch, Ph.D., that SFC had ...
    6-1-2013
  • Biotechs Need to Walk the Walk on Drug Value
    In June 2012, Massachusetts joined with Abbott, Biogen Idec, EMD Serono, Janssen, Merck & Co., Pfizer, and Sunovion Pharmaceuticals to form the Massachusetts Neuroscience ...
    5-15-2013
  • Companion Diagnostics: 52 Pick-Up
    ... Drug and specific cancer indication not disclosed. Financial terms not disclosed. Abbott (Abbott Molecular) and Merck & Co. Agreement announced March 6, 2012 Collaboration to ...
    5-9-2013

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Top Paid Women in Biopharma

Do you think the women on our list of the 20 top paid women executives in biopharma are underpaid?

Suggest a Poll